The National Institutes of Health (NIH) COVID-19 Treatment Panel has released recommendations that include an order of preference for which therapeutics to use to treat nonhospitalized patients with mild to moderate COVID-19 who are at high risk of severe disease progression.
The panel’s recommendation includes therapeutics in the following order of preference, with specific dosing instructions available in the recommendation:
- Nirmatrelvir with ritonavir (Paxlovid);
- Sotrovimab;
- Remdesivir; and
- Molnupiravir.
Ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir are the two new oral antiviral medications that the Food and Drug Administration issued emergency use authorizations for in late December. Sotrovimab and remdesivir are administered as IV infusions.
Along with dosing recommendations, the panel’s statement includes considerations for the new oral medications, clinical trial results, and other information.
Last Updated On
March 10, 2022
Originally Published On
January 05, 2022